EASTONBIOPHARMACEUTICALS(SH:688513)2025-04-24 14:10Financial Performance - The company's operating revenue for Q1 2025 was CNY 305,640,342.42, a decrease of 2.97% compared to CNY 314,990,089.28 in the same period last year[4] - Net profit attributable to shareholders was CNY 60,590,351.64, down 19.22% from CNY 75,010,084.96 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 46,468,704.84, a decrease of 10.79% compared to CNY 52,091,879.13 in the previous year[4] - The net profit for Q1 2025 was CNY 60,590,351.64, a decrease of 19.3% compared to CNY 75,010,084.96 in Q1 2024[20] - Operating profit for Q1 2025 was CNY 62,469,083.72, down from CNY 80,220,974.65 in the same period last year, reflecting a decline of 22.1%[20] - The company reported a net profit margin of approximately 15.1% for Q1 2025, based on the revenue and operating costs figures[19] - The total comprehensive income for Q1 2025 was CNY 60,590,351.64, a decrease of 19.3% from CNY 75,010,084.96 in Q1 2024[21] Cash Flow and Investments - The net cash flow from operating activities was CNY 48,957,799.77, down 31.90% from CNY 71,892,080.50 year-on-year[4] - The cash flow from operating activities for Q1 2025 was CNY 48,957,799.77, a decrease of 32.0% compared to CNY 71,892,080.50 in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY 551,307,978.14 in Q1 2025, compared to a net inflow of CNY 41,296,601.12 in Q1 2024[24] - Cash and cash equivalents as of March 31, 2025, were RMB 496,753,707.66, down from RMB 971,404,996.50 as of December 31, 2024[14] - Cash and cash equivalents at the end of Q1 2025 were CNY 490,995,537.76, down from CNY 816,632,829.91 at the end of Q1 2024[25] Research and Development - Research and development expenses totaled CNY 61,855,238.88, representing 20.24% of operating revenue, an increase of 0.19 percentage points compared to 20.05% last year[5] - Research and development expenses rose to CNY 61,097,854.94 in Q1 2025, up 12.5% from CNY 54,184,914.96 in Q1 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,460,845,346.04, an increase of 1.79% from CNY 3,400,127,500.60 at the end of the previous year[5] - Total assets increased to RMB 3,460,845,346.04 as of March 31, 2025, compared to RMB 3,400,127,500.60 at the end of 2024[16] - Total liabilities decreased slightly to RMB 697,883,870.78 from RMB 702,205,924.57 at the end of 2024[17] - Shareholders' equity increased to RMB 2,762,961,475.26 as of March 31, 2025, compared to RMB 2,697,921,576.03 at the end of 2024[17] - Inventory as of March 31, 2025, was RMB 213,618,891.26, up from RMB 190,086,164.97 at the end of 2024[15] - Short-term borrowings increased to RMB 103,385,606.87 from RMB 74,437,854.77 at the end of 2024[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,091[10] - The largest shareholder, Wang Ying, holds 34.89% of the shares, totaling 61,593,000 shares[11] Earnings Per Share - The basic and diluted earnings per share for Q1 2025 were both CNY 0.34, down from CNY 0.43 in Q1 2024[21] Financial Expenses - The company incurred financial expenses of CNY -1,829,246.74 in Q1 2025, compared to CNY -944,567.73 in Q1 2024, indicating an increase in financial costs[20]